ライフサイエンスコーパス: intraventricular

1 nts were imaged with approximately 74 MBq of intraventricular (124)I-omburtamab via an Ommaya reservo

2 eurologic effects, such as ventriculomegaly, intraventricular adhesions, subependymal cysts, intracer

3 The aim is to review the role of intraventricular administration of antimicrobial agents

4 Intraventricular administration of antimicrobials may be

5 e to seizure-induced hippocampal damage, and intraventricular administration of leptin protects neuro

6 Consistent with this finding, intraventricular administration of melanotan-2, an analo

7 Intraventricular administration of MSCs in ICH rat model

8 In vivo intraventricular administration of the Lck-I using an or

9 In addition, intraventricular administration of VEGFB restored neurog

10 day-30 mortality and partially mitigated by intraventricular alteplase.

11 dymal denudation, and damage and scarring of intraventricular and parenchymal (glia-lymphatic) CSF pa

12 Intraventricular anti-miR-155 treatment derepressed micr

13 This article discusses indications for intraventricular antimicrobial agents, choice of antibio

14 Intraventricular baclofen pretreatment in rats subjected

15 Separate studies undertaken using an intraventricular balloon revealed no detrimental effects

16 Contractility was monitored by intraventricular balloon, energetics by (31)P nuclear MR

17 tfeeding < 3 months, artificial ventilation, intraventricular bleeding, and other perinatal adverse e

18 oid (Hijdra Sum Score 17 vs 14, p<0.001) and intraventricular blood (median IVH sum score 2 vs 1, p<0

19 h poor clinical grade, more subarachnoid and intraventricular blood seen on admission computed tomogr

20 hniques to remove clot, techniques to remove intraventricular blood, and management of intracranial p

21 cerebral ventricular drainage, 2) meticulous intraventricular catheter handling, 3) cerebrospinal flu

22 No evidence of intraventricular clot was found.

23 In patients without AVB and no intraventricular conduction abnormalities, ventricular p

24 in 27 patients (left bundle branch block 17, intraventricular conduction defect 5, and right ventricu

25 Compared with women with no BBB, LBBB, and intraventricular conduction defect were strong predictor

26 io, 3.53; confidence interval, 2.14-5.81 for intraventricular conduction defect).

27 LBBB, intraventricular conduction defect, and RBBB combined wi

28 and indetermined-type BBBs (LBBB, RBBB, and intraventricular conduction defect, respectively).

29 proved cardiac contractility and ameliorated intraventricular conduction defects in LmnaH222P/H222P m

30 ubule cytoskeleton using Paclitaxel improved intraventricular conduction defects.

31 bundle branch block (HR=1.01, P=0.975), and intraventricular conduction delay (HR=1.31, P=0.172).

32 block (RBBB) in 48 patients, and nonspecific intraventricular conduction delay (IVCD) was present in

33 ure patients with narrow QRS and nonspecific intraventricular conduction delay (NICD) display a relat

34 mong Medicare-aged patients with nonspecific intraventricular conduction delay (NICD) versus right bu

35 of death in these patients who also have an intraventricular conduction delay and are treated with C

36 Left-sided intraventricular conduction delay is associated with mor

37 c imaging could be a more specific marker of intraventricular conduction delay rather than the surrog

38 of patients with left bundle branch block or intraventricular conduction delay treated with cardiac r

39 with advanced chronic heart failure (HF) and intraventricular conduction delay treated with optimal p

40 (LBBB; including right bundle branch block, intraventricular conduction delay) did not have clinical

41 h block, 18 left bundle branch block, and 12 intraventricular conduction delay).

42 Over half the affected cohort (28/52) had intraventricular conduction delay, or incomplete right b

43 ents with poor left ventricular function and intraventricular conduction delay.

44 icular ejection fraction of 35% or less, and intraventricular conduction delays (QRS > 120 ms), altho

45 for patients with advanced heart failure and intraventricular conduction delays and ventricular dyssy

46 ong patients with advanced heart failure and intraventricular conduction delays, but the cost effecti

47 block (LBBB), and in 15, it was nonspecific intraventricular conduction disturbance (NICD).

48 BB QRS pattern (right bundle-branch block or intraventricular conduction disturbances).

49 branch block, and 308 (17%) with nonspecific intraventricular conduction disturbances.

50 ction fraction of 30% or less, and prolonged intraventricular conduction with a QRS duration of 130 m

51 ECG QRS duration, a measure of cardiac intraventricular conduction, varies approximately 2-fold

52 raction order, and entropy (E), a measure of intraventricular contraction disorder, and interventricu

53 novel indices of synchrony (S), a measure of intraventricular contraction order, and entropy (E), a m

54 y awake rats to follow the redistribution of intraventricular contrast agent entrained to the light-d

55 Intraventricular corticosterone attenuated cocaine self-

56 te contraction, postsystolic shortening, and intraventricular delay were analyzed using 2-dimensional

57 Intraventricular delivery of EVP4593 in YAC128 mice resc

58 ded target cytotoxic concentrations after an intraventricular dose, but lumbar CSF concentrations 2 h

59 be easily achieved in ventricular CSF after intraventricular dosing.

60 ariety of schedules either by intralumbar or intraventricular drug delivery.

61 ariety of schedules either by intralumbar or intraventricular drug delivery.

62 ariety of schedules either by intralumbar or intraventricular drug delivery.

63 Patients with intraventricular dyssynchrony on echocardiography were r

64 is characteristic for LBBB and results from intraventricular dyssynchrony.

65 re at the scene (p = .045), greater rates of intraventricular extension (p < .0001), and radiologic s

66 Scale (NIHSS) score, larger ICH, presence of intraventricular extension and use of proxy responders.

67 oedema with increased intracranial pressure, intraventricular extension of haemorrhage with hydroceph

68 BACKGROUND AND Intraventricular extension of intracerebral haemorrhage

69 Intraventricular extension of intracerebral haemorrhage

70 Intraventricular extension of intracerebral hemorrhage (

71 (modified Rankin Scale score, 3-6), any new intraventricular extension or an increase in the modifie

72 igher diastolic blood pressure at the scene, intraventricular extension, and radiologically evident h

73 IVH treatment by intraventricular fibrinolysis (IVF) was recently linked

74 , hypertrophy-related fetal gene expression, intraventricular fibrosis, cardiac apoptosis, and oxidat

75 his study sought to understand the impact of intraventricular flow patterns on filling and to assess

76 Intraventricular fluid dynamics can be assessed clinical

77 Thus, intraventricular fluid mechanics are an important determ

78 atients, designated PRE based on a decreased intraventricular gradient during exercise.

79 ients had no obstruction and 38 exhibited an intraventricular gradient, 9 of whom exhibited a decreas

80 paradoxical situations in which significant intraventricular gradients (>50 mm Hg) at rest occur in

81 t common underlying diagnoses were perinatal intraventricular haemorrhage (35.3%) and malformations (

82 oor outcome, but the significance of delayed intraventricular haemorrhage (dIVH) is less well defined

83 oor outcome, but the significance of delayed intraventricular haemorrhage (dIVH) is less well defined

84 eline and 24 h CTs, with dIVH defined as new intraventricular haemorrhage (IVH) on the latter scan.

85 icular haemorrhage volume (IVH) with/without intraventricular haemorrhage (IVH) over 24 h were estima

86 ntracerebral haemorrhage of 10-100 mL and no intraventricular haemorrhage admitted within 48 h of ict

87 INTERPRETATION: In patients with intraventricular haemorrhage and a routine extraventricu

88 Intraventricular haemorrhage is a major complication of

89 Intraventricular haemorrhage is a subtype of intracerebr

90 As intraventricular haemorrhage leads to an inflammatory re

91 cerebral haemorrhage volume less than 30 mL, intraventricular haemorrhage obstructing the 3rd or 4th

92 stently higher in the forebrain of pups with intraventricular haemorrhage relative to pups without in

93 mine whether a greater frequency of complete intraventricular haemorrhage removal via alteplase produ

94 29], p=0.420) was found after adjustment for intraventricular haemorrhage size and thalamic intracere

95 age size, age, Glasgow Coma Scale, stability intraventricular haemorrhage size, and clot location).

96 5% CI 1.2 to 3.5; p=0.01) and higher SAH and intraventricular haemorrhage sum scores (OR 1.05, 95% CI

97 c regression, and (2) of increased haematoma+intraventricular haemorrhage volume (IVH) with/without i

98 Intraventricular haemorrhage was diagnosed by head ultra

99 atic measurement methods; shape, density and intraventricular haemorrhage were also assessed.

100 The pups with intraventricular haemorrhage were treated with inhibitor

101 To this end, we used our rabbit model of intraventricular haemorrhage where premature pups, deliv

102 e aimed to test whether attempting to remove intraventricular haemorrhage with alteplase versus salin

103 ase-2 in the inflammatory cascade induced by intraventricular haemorrhage, and cyclooxygenase-2-inhib

104 le score, increasing ICH volume, presence of intraventricular haemorrhage, and deep/infratentorial IC

105 rtality, bronchopulmonary dysplasia, sepsis, intraventricular haemorrhage, periventricular leukomalac

106 uperficial intracerebral haemorrhage without intraventricular haemorrhage.

107 ricular haemorrhage relative to pups without intraventricular haemorrhage.

108 brain damage initiated by the development of intraventricular haemorrhage.

109 izing brain damage in premature infants with intraventricular haemorrhage.

110 els were comparable in pups with and without intraventricular haemorrhage.

111 d gliosis around the ventricles of pups with intraventricular haemorrhage.

112 CNS due to repeated chronic subarachnoid or intraventricular haemorrhage.

113 Exclusion criteria were pure intraventricular haemorrhage; intracerebral haemorrhage

114 pro-inflammatory cytokines were elevated in intraventricular haemorrhage; whether their suppression

115 (10.7 [23.1] vs 9.2 [20.7]; p = 0.900), and intraventricular hematoma expansion (14.5 [63.2] vs 6.1

116 eath, chronic lung disease, neonatal sepsis, intraventricular hemorrhage >grade 2, periventricular le

117 8.3%), respiratory distress syndrome (8.3%), intraventricular hemorrhage (1.4%), intrauterine fetal d

118 al, 76.3; medical, 6.17), sepsis (2.66), and intraventricular hemorrhage (1.97) (P < 0.005).

119 8%] vs 13 of 103 12.6%]; P = .04) and severe intraventricular hemorrhage (11 infants [10.3%] vs 23 [2

120 5.3% [95% CI, 14.4%-16.3%]), death or severe intraventricular hemorrhage (17.5% [95% CI, 16.5%-18.6%]

121 Less platelet activity was associated with intraventricular hemorrhage (516.5 [interquartile range

122 ce of necrotizing enterocolitis, sepsis, and intraventricular hemorrhage (all grades).

123 fants of women receiving ANS included severe intraventricular hemorrhage (aRR = 0.68; 95% CI, 0.58-0.

124 Low-grade germinal matrix-intraventricular hemorrhage (GM-IVH) is the most common

125 s were categorized into three classes: 1) no intraventricular hemorrhage (grade 0); 2) mild-moderate

126 cular hemorrhage (grade 0); 2) mild-moderate intraventricular hemorrhage (grades 1-2, i.e., germinal

127 lar dilatation, respectively); and 3) severe intraventricular hemorrhage (grades 3-4, i.e., intravent

128 Thrombocytopenia and intraventricular hemorrhage (IVH) are common among very-

129 Intraventricular hemorrhage (IVH) in premature infants r

130 Intraventricular hemorrhage (IVH) in preterm infants lea

131 Intraventricular hemorrhage (IVH) is a major complicatio

132 Intraventricular hemorrhage (IVH) is a negative prognost

133 Intraventricular hemorrhage (IVH) remains a major cause

134 Intraventricular hemorrhage (IVH) results in neural cell

135 ventricles due to CSF accumulation following intraventricular hemorrhage (IVH), is a common disease u

136 ICH volume (p = 0.025), intraventricular hemorrhage (p = 0.019), presence of mic

137 rophylactic indomethacin may decrease Severe Intraventricular Hemorrhage (SIVH).

138 et function on admission are associated with intraventricular hemorrhage and death after ICH.

139 The risk of death or severe intraventricular hemorrhage and death or necrotizing ent

140 es is uniquely associated with both neonatal intraventricular hemorrhage and death.

141 th or chronic lung disease as well as severe intraventricular hemorrhage and periventricular leukomal

142 Perinatal asphyxia, intraventricular hemorrhage and stroke are common causes

143 Acute intracranial hemorrhage and intraventricular hemorrhage are devastating disorders.

144 l-age infants with low-grade periventricular-intraventricular hemorrhage are not significantly differ

145 arly-onset sepsis and severe periventricular-intraventricular hemorrhage as compared with unexposed n

146 ed to preempt the occurrence and severity of intraventricular hemorrhage as detected by ultrasound.

147 mortality, nosocomial infection, and severe intraventricular hemorrhage but not of 28-day mortality

148 cord milking group died or developed severe intraventricular hemorrhage compared with 8% (20/238) of

149 Thrombocytopenia was a risk factor for intraventricular hemorrhage during the first 7 days of l

150 Detection of intraventricular hemorrhage during the first postnatal d

151 prising an imbalance in the number of severe intraventricular hemorrhage events by study group was ob

152 or neonatal morbidity (specifically, without intraventricular hemorrhage grade 3-4, cystic periventri

153 severe neonatal brain injury, defined as an intraventricular hemorrhage grade of 3 or greater or cys

154 or severe neonatal morbidity, defined as an intraventricular hemorrhage grade of 3 or greater, cysti

155 Early bedside detection of intraventricular hemorrhage holds promise for advancing

156 Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage III trial and the Minimally

157 njection of thrombin (20U) was used to model intraventricular hemorrhage in adult rats.

158 rain activity that preempt the occurrence of intraventricular hemorrhage in extremely preterm infants

159 premature ovine fetuses and the incidence of intraventricular hemorrhage in premature infants.

160 The etiology of intraventricular hemorrhage in preterm infants is multif

161 ns between sodium intake, hypernatremia, and intraventricular hemorrhage in preterm infants.

162 roencephalography preempts the occurrence of intraventricular hemorrhage in the extremely preterm.

163 stically significantly higher rate of severe intraventricular hemorrhage in the umbilical cord milkin

164 m appears to be a modifiable risk factor for intraventricular hemorrhage in very low birth weight inf

165 ompared with no abnormality, germinal matrix/intraventricular hemorrhage increased risk for current m

166 Diagnostic discrimination of intraventricular hemorrhage infants using measures of bu

167 f electroencephalography bursts found in the intraventricular hemorrhage infants were significantly s

168 Intraventricular hemorrhage is a common neurologic compl

169 Low-grade periventricular-intraventricular hemorrhage is a common neurologic morbi

170 he management of intracranial hemorrhage and intraventricular hemorrhage is complex.

171 Early bedside detection of intraventricular hemorrhage is crucial to enabling timel

172 RD, -0.14 [95% CI, -0.25 to -0.04]) and for intraventricular hemorrhage of all grades (RR, 0.62 [95%

173 d treatment group was significant for severe intraventricular hemorrhage only (P = .003); among infan

174 gorized as either (1) germinal matrix and/or intraventricular hemorrhage or (2) parenchymal lesions a

175 ecrotizing enterocolitis or death and severe intraventricular hemorrhage or death.

176 Secondary outcomes included secondary intraventricular hemorrhage or hydrocephalus upon follow

177 r absence of chronic lung disease and severe intraventricular hemorrhage or periventricular leukomala

178 Chronic lung disease and severe intraventricular hemorrhage or periventricular leukomala

179 cance of intracranial hypertension in severe intraventricular hemorrhage requiring extraventricular d

180 w cerebral perfusion pressure in obstructive intraventricular hemorrhage requiring extraventricular d

181 Patients with intracranial hemorrhage and intraventricular hemorrhage should be cared for in an in

182 y outcome was a composite of death or severe intraventricular hemorrhage to determine noninferiority

183 rainage placement ipsilateral to the largest intraventricular hemorrhage volume (p=.001), but not wit

184 mained significantly associated with initial intraventricular hemorrhage volume (p=.002) and extraven

185 20 mm Hg), both intracerebral hemorrhage and intraventricular hemorrhage volume, and pulse pressure.

186 Hg and initial intracerebral hemorrhage and intraventricular hemorrhage volumes were independent pre

187 Severe intraventricular hemorrhage was 7.2% in RNE hospitals an

188 Grade II to IV intraventricular hemorrhage was associated with increase

189 New or increased intraventricular hemorrhage was observed in 18% (8 of 45

190 The association of high sodium intake with intraventricular hemorrhage was of similar magnitude to

191 ally significant difference in death, severe intraventricular hemorrhage was statistically significan

192 ts born at 23 to 27 weeks' gestation, severe intraventricular hemorrhage was statistically significan

193 ys or younger and participants with isolated intraventricular hemorrhage were excluded.

194 traventricular hemorrhage (grades 3-4, i.e., intraventricular hemorrhage with ventricular dilatation

195 es 1-2, i.e., germinal matrix hemorrhages or intraventricular hemorrhage without ventricular dilatati

196 rhage; 4, thick subarachnoid hemorrhage with intraventricular hemorrhage).

197 stay mortality, 12.9% (9278/71,936); severe intraventricular hemorrhage, 7.6% (4842/63,525); and inf

198 ventricular drainage in patients with severe intraventricular hemorrhage, although intracranial press

199 severe retinopathy of prematurity and severe intraventricular hemorrhage, and 8 years to achieve the

200 nimally invasive interventions, clearance of intraventricular hemorrhage, and adequate blood pressure

201 ibutor to the risk of death, death or severe intraventricular hemorrhage, and death or necrotizing en

202 during extraventricular drainage for severe intraventricular hemorrhage, and level and duration pred

203 Intracerebral hemorrhage, intraventricular hemorrhage, and perihematomal edema vol

204 Hematoma expansion, intraventricular hemorrhage, and reversal of anticoagula

205 prematurity, bronchopulmonary dysplasia, and intraventricular hemorrhage, as well as death.

206 ith substantial neonatal morbidities such as intraventricular hemorrhage, bronchopulmonary dysplasia,

207 te of a composite outcome of death or severe intraventricular hemorrhage, but there was a statistical

208 following adverse outcomes: grade III or IV intraventricular hemorrhage, cystic periventricular leuk

209 Rates of secondary intraventricular hemorrhage, hydrocephalus, and thromboe

210 Coma Scale, intracerebral hemorrhage volume, intraventricular hemorrhage, infratentorial hemorrhage,

211 cTI elevation included poor clinical grade, intraventricular hemorrhage, loss of consciousness at ic

212 seizure, cardiomyopathy, periventricular or intraventricular hemorrhage, necrotizing enterocolitis,

213 h, severe retinopathy of prematurity, severe intraventricular hemorrhage, necrotizing enterocolitis,

214 CLD alone, death alone, air leakage, severe intraventricular hemorrhage, neurodevelopmental impairme

215 two points; infratentorial PICH, two points; intraventricular hemorrhage, one point; PICH volume grea

216 enterocolitis, sepsis, chronic lung disease, intraventricular hemorrhage, or cholestasis.

217 h by 18 to 22 months; hospital death; death, intraventricular hemorrhage, or periventricular leukomal

218 severe complications (defined as high-grade intraventricular hemorrhage, surgery for abdominal compl

219 activity prior to ultrasound confirmation of intraventricular hemorrhage.

220 ; p < 0.015) than in preterm infants without intraventricular hemorrhage.

221 itis, retinopathy of prematurity, and severe intraventricular hemorrhage.

222 ounts were not significantly associated with intraventricular hemorrhage.

223 Low-grade periventricular-intraventricular hemorrhage.

224 ms leading to poor outcomes in patients with intraventricular hemorrhage.

225 days after birth; and severe (grade 3 or 4) intraventricular hemorrhage.

226 elial cell wall, thereby preventing neonatal intraventricular hemorrhage.

227 consequences of intracranial hemorrhage and intraventricular hemorrhage.

228 he acute care of intracranial hemorrhage and intraventricular hemorrhage.

229 ns between sodium intake, hypernatremia, and intraventricular hemorrhage.

230 contribute to poor outcomes in hypertensive intraventricular hemorrhage.

231 rrhage; 2, thin subarachnoid hemorrhage with intraventricular hemorrhage; 3, thick [>= 1 mm] subarach

232 on, necrotic foci, periventricular cysts and intraventricular hemorrhages were observed distal to sta

233 apy, we conducted the first phase 1 study of intraventricular immunochemotherapy in patients with rec

234 gadolinium imaging depicted parenchymal and intraventricular inflammation.

235 Intraventricular infusion of 5HT2C agonist or antagonist

236 In contrast, intraventricular infusion of a soluble form of the Nogo

237 ately followed by 3 or 14 days of continuous intraventricular infusion of either human recombinant de

238 We report that intraventricular infusion of ganglioside GM1 induces pho

239 Intraventricular infusion of Shh and a Shh receptor inhi

240 Intraventricular infusion of sNgR for 1 month results in

241 Intraventricular infusion of ss-siRNA produced selective

242 d in R6/2 mice treated only with AdBDNF, and intraventricular infusion of the mitotic inhibitor Ara-C

243 phosphate-buffered saline placebo via direct intraventricular infusion.

244 Intraventricular injected AFSC that homed within the glo

245 Intraventricular injected EVs were taken up by CD11b/IBA

246 ide in the subventricular zone of the brain, intraventricular injection has been used as an administr

247 Intraventricular injection of 15d-Delta(12,14)-prostagla

248 re, by inhibiting SDF1 signaling in utero by intraventricular injection of a receptor antagonist, we

249 memory deficits in wild type mice induced by intraventricular injection of Abeta4-42.

250 Intraventricular injection of an MrgA1 ligand increased

251 y neurons in the mouse neocortex by in utero intraventricular injection of enhanced green fluorescent

252 Second, intraventricular injection of HA oligosaccharide reduced

253 sistant to the excitotoxic damage induced by intraventricular injection of kainic acid.

254 ic responses of rodents to the peripheral or intraventricular injection of many individual neurotrans

255 Intraventricular injection of tPA or active PDGF-CC, in

256 We found that after intraventricular injection, a spread of CSF tracers occu

257 Within 15 to 30 min following intraventricular injection, there is only diffuse, non-s

258 dogenous choroid plexus epithelium following intraventricular injection.

259 ne transfer to the subventricular zone after intraventricular injection.

260 ctions of 5-bromo-2'-deoxyuridine (BrdU) and intraventricular injections of replication-deficient ret

261 toxicity, pharmacokinetics, and dosimetry of intraventricular iodine-131-labeled monoclonal antibody

262 Improgan (60, 100 and 140 microg, intraventricular [ivt]) elicited significant decreases i

263 atrioventricular, interventricular, and left intraventricular levels.

264 ow that there is a finite risk of forming an intraventricular mass, presumably from the cellular debr

265 significantly reduced LV volume indices and intraventricular mechanical delay, and improved LV eject

266 1 +/- 29 ms to 202 +/- 39 ms, p < 0.001) and intraventricular mechanical dyssynchrony (15 +/- 26 ms t

267 ntional systemic chemotherapy without serial intraventricular methotrexate injection failed to achiev

268 Systemic chemotherapy and intraventricular methotrexate led to favorable survival

269 on a modified HIT SKK 2000 regimen excluding intraventricular methotrexate, aiming to achieve similar

270 ic medulloblastoma by systemic chemotherapy, intraventricular methotrexate, and risk-adapted local ra

271 Intraventricular NPQ/spexin and NPQ 53-70 also produced

272 tissue Doppler imaging techniques to assess intraventricular opposing wall delay or dispersion of ti

273 nd other adverse outcomes after placement of intraventricular or interventricular stents for this ind

274 f the ventricular system, presence of raised intraventricular pressure and topographic relationships

275 of systolic LV function such as the ejection intraventricular pressure difference (EIVPD) and the sys

276 The Doppler-derived peak ejection intraventricular pressure difference should be preferred

277 oninvasive indices tested, the peak ejection intraventricular pressure difference showed the best cor

278 ion analyses demonstrated that peak ejection intraventricular pressure difference was less sensitive

279 s color M-mode Doppler (CMM) can quantify LV intraventricular pressure gradients (IVPGs).

280 Favorable vortical effects on intraventricular pressure gradients were observed in the

281 In contrast, application of short-lived intraventricular pressure surges neither triggers PVEM n

282 d mild chamber remodelling with ageing while intraventricular pressure-volume loop analysis showed si

283 improvement in cardiac functions measured by intraventricular pressure-volume loops.

284 We conclude that intraventricular rituximab in combination with MTX is fe

285 Phase I study showed that intraventricular rituximab plus methotrexate is feasible

286 KEY POINTS: Phase I study showed that intraventricular rituximab plus methotrexate is feasible

287 Fourteen patients received 10 mg or 25 mg intraventricular rituximab twice weekly for 4 weeks, wit

288 The safety profile of intraventricular rituximab was defined in 10 patients.

289 ed a first complete response of CNS NHL with intraventricular rituximab/MTX, including 1 with CNS lym

290 alternate dosing between the intralumbar and intraventricular routes was tested.

291 as administered, alternating intralumbar and intraventricular routes.

292 LVID), wall thicknesses (posterior [PWT] and intraventricular septum [IVST]), and relative wall thick

293 aminepentaacetic acid injection into the CSF intraventricular space followed by nuclear medicine imag

294 the five hemorrhage subtypes (subarachnoid, intraventricular, subdural, epidural, and intraparenchym

295 h central nervous system (CNS) tumors before intraventricular therapy has not been described.

296 idered when attempting to ensure appropriate intraventricular therapy in the pediatric population.

297 tion of a stable scar and protection against intraventricular thrombi after acute infarction.

298 s in significant shortening of the diastolic intraventricular time delay which is closely related to

299 Intraventricular UTP injection transiently decreased blo

300 We used neonatal intraventricular viral injections to express VAPB or YFP